MX2013007773A - Terapia anticancer con inhibidores duales de aurora quinasa / mek. - Google Patents

Terapia anticancer con inhibidores duales de aurora quinasa / mek.

Info

Publication number
MX2013007773A
MX2013007773A MX2013007773A MX2013007773A MX2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A MX 2013007773 A MX2013007773 A MX 2013007773A
Authority
MX
Mexico
Prior art keywords
aurora kinase
mek inhibitors
anticancer therapy
dual aurora
dual
Prior art date
Application number
MX2013007773A
Other languages
English (en)
Inventor
Flavio Solca
Ulrich Guertler
Irene Waizenegger
Ulrike Tontsch-Grunt
Michael Sanderson
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013007773A publication Critical patent/MX2013007773A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención describe terapias anti-cáncer que comprenden el uso de inhibidores duales de Aurora quinasa / MEK de acuerdo con lo descrito en la presente memoria.
MX2013007773A 2011-01-12 2012-01-12 Terapia anticancer con inhibidores duales de aurora quinasa / mek. MX2013007773A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11150775 2011-01-12
EP11161776 2011-04-08
EP11167688 2011-05-26
PCT/EP2012/050466 WO2012095505A1 (en) 2011-01-12 2012-01-12 Anticancer therapy with dual aurora kinase / mek inhibitors

Publications (1)

Publication Number Publication Date
MX2013007773A true MX2013007773A (es) 2013-08-12

Family

ID=45463628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007773A MX2013007773A (es) 2011-01-12 2012-01-12 Terapia anticancer con inhibidores duales de aurora quinasa / mek.

Country Status (13)

Country Link
US (2) US20130004481A1 (es)
EP (1) EP2663303A1 (es)
JP (1) JP2014507408A (es)
KR (1) KR20140043314A (es)
CN (1) CN103429238A (es)
AR (1) AR084831A1 (es)
AU (1) AU2012206511A1 (es)
BR (1) BR112013017671A2 (es)
CA (1) CA2824480A1 (es)
EA (1) EA201300810A1 (es)
MX (1) MX2013007773A (es)
UY (1) UY33866A (es)
WO (1) WO2012095505A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP3246332B1 (en) 2010-01-12 2019-07-10 Siemens Healthcare Diagnostics Inc. Oligonucleotides and methods for detecting pik3ca mutations
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
US20130122005A1 (en) * 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
PT2892535T (pt) * 2012-09-04 2021-12-15 Novartis Ag Método de tratamento adjuvante do cancro
US20150272952A1 (en) * 2012-10-22 2015-10-01 Glaxosmithkline Llc Combination
JP2015534987A (ja) * 2012-10-22 2015-12-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 組合せ
CA2889530A1 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
MY181085A (en) 2013-03-21 2020-12-17 Novartis Ag Combination therapy
US20160058751A1 (en) * 2013-03-28 2016-03-03 Cellworks Group, Inc. Composition and method for treating cancer
AU2014273946B2 (en) * 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
EP3082779B1 (en) * 2013-12-20 2023-06-07 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
FI3698790T3 (fi) * 2014-02-07 2023-06-06 Verastem Inc Menetelmiä epänormaalin solukasvun hoitamiseksi
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP6644717B2 (ja) 2014-03-14 2020-02-12 ジェネンテック, インコーポレイテッド 異種ポリペプチドを分泌させるための方法及び組成物
WO2015164862A1 (en) * 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
CN104372103B (zh) * 2014-12-05 2017-05-24 武汉友芝友医疗科技股份有限公司 一种nras基因突变检测试剂盒
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
CN105063177A (zh) * 2015-05-14 2015-11-18 广州和实生物技术有限公司 Braf基因多点突变单管快速检测方法及试剂盒
JP2018520164A (ja) * 2015-07-09 2018-07-26 ザ ジャクソン ラボラトリー プロテアソームインヒビターと組み合わせてmekインヒビターを投与することによりがんを処置する方法
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN107119331A (zh) * 2017-05-15 2017-09-01 重庆市肿瘤研究所 肿瘤放射治疗毒性基因突变文库的构建方法
KR20200041387A (ko) * 2017-09-08 2020-04-21 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
CN108324713B (zh) * 2018-01-25 2020-09-01 三峡大学 一种烷基吲哚酮衍生物的应用及抗甲状腺肿瘤药物
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230201198A1 (en) * 2020-04-27 2023-06-29 Verastem, Inc. Methods of treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2646638A1 (en) 2006-04-24 2007-11-01 Boehringer Ingelheim International Gmbh 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
EP2167465A1 (en) 2007-06-12 2010-03-31 Boehringer Ingelheim International GmbH Indolinone derivatives and their use in treating disease-states such as cancer
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合
PE20110213A1 (es) * 2008-07-29 2011-04-16 Boehringer Ingelheim Int Derivados de indolinona como inhibidores de quinasa

Also Published As

Publication number Publication date
CA2824480A1 (en) 2012-07-19
EP2663303A1 (en) 2013-11-20
BR112013017671A2 (pt) 2018-09-18
WO2012095505A1 (en) 2012-07-19
UY33866A (es) 2012-07-31
EA201300810A1 (ru) 2014-01-30
CN103429238A (zh) 2013-12-04
US20130004481A1 (en) 2013-01-03
AU2012206511A1 (en) 2013-07-04
AR084831A1 (es) 2013-06-26
US20140194442A1 (en) 2014-07-10
KR20140043314A (ko) 2014-04-09
JP2014507408A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
MX2013007773A (es) Terapia anticancer con inhibidores duales de aurora quinasa / mek.
PH12017501176A1 (en) Pyruvate kinase activators for use therapy
IL238548A0 (en) Adjuvant treatment of a kinase inhibitor from the tec family
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
MX355728B (es) Inhibidores de cinasas.
EP3132033A4 (en) Beta-lactamases with improved properties for therapy
EP3210129A4 (en) Dual mode gaming system with bingo progressive plug-in
EP2822558A4 (en) PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY
IN2014DN00180A (es)
EP2994155A4 (en) Targeting the egfr-sglt1 interaction for cancer therapy
EP3053578A4 (en) Combination cancer therapy using azabicyclo compound
EP3256115A4 (en) COMBINATION CANCER THERAPY
EP3267975A4 (en) Polymer-drug conjugates for combination anticancer therapy
PL2748147T3 (pl) Podstawione 2-alkilo-1-okso-n-fenylo-3-heteroarylo-1,2,3,4- tetrahydroizochinolino-4-karboksamidy do terapii przeciwmalarycznych
EP3220920A4 (en) Combination therapy effective against microorganisms, including drug resistant microorganisms
IN2014DN08477A (es)
EP3007704A4 (en) Combination therapy
WO2012106473A3 (en) Dosing for treatment with anti-egfl7 antibodies
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
EP3280261A4 (en) Anticancer therapeutic agents
MX2015001134A (es) Compuestos terapeuticos.
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (ru) Применение полентара как средства фригопротекторного действия
AU2012902291A0 (en) Combination Therapy
AU2012900695A0 (en) Bandbuilder.com